New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:44 EDTLGND, MRNSMarinus Pharmaceuticals enters into agreement with CyDex Pharmaceuticals
Marinus Pharmaceuticals (MRNS) announced that it has entered into an agreement with CyDex Pharmaceuticals, a wholly owned subsidiary of Ligand Pharmaceutical (LGND), for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.
News For MRNS;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
09:15 EDTLGNDLigand management to meet with Craig Hallum
Meeting to be held in Kansas City on May 28 hosted by Craig Hallum.
May 21, 2015
11:09 EDTMRNSMarinus Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use